Coronavirus disease 2019 (COVID-19)
Adult: For the treatment of mild to moderate cases in nonhospitalised patients with confirmed positive SARS-CoV-2 diagnostic test result who have at least 1 risk factor for developing severe COVID-19, and in whom alternative COVID-19 treatment options approved or authorised by the US FDA are inaccessible or not clinically appropriate: 800 mg 12 hourly for 5 days. Initiate therapy as soon as possible following diagnosis of COVID-19 and within 5 days of symptom onset. Safety and efficacy of therapy beyond 5 consecutive days have not been established. Missed dose: If a dose is missed within 10 hours of the time it is usually taken, take the missed dose as soon as possible then return to the normal dosing schedule. If the dose is missed by >10 hours, skip the missed dose and instead take the next dose at the usual dosing schedule. Do not double the dose to make up for a missed dose.
Child: <18 years Currently, the safety and efficacy of molnupiravir in children and adolescents have not been established; until such data are available, use in this age group is not recommended.
Elderly: Same as adult dose.
Child: <18 years Currently, the safety and efficacy of molnupiravir in children and adolescents have not been established; until such data are available, use in this age group is not recommended.
Elderly: Same as adult dose.